Carol A Aghajanian MD

Oncology•New York, NY

Gynecologic Cancer

Chief, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center

Request appointment

160 East 53rd StreetNew York, NY 10022
Book by Phone+1(405) 497-8724

Overview of Dr. Aghajanian

Dr. Carol Aghajanian is the Chief of Gynecologic Medical Oncology at Memorial Sloan Kettering Cancer Center and Professor of Medicine, Weill Cornell Medical College, New York, NY.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1989 - 1992
State University of New York Downstate Medical Center College of MedicineClass of 1989, MD, Cum Laude, Alpha Omega Alpha
Boston UniversityBA, Biology, Summa Cum Laude, Phi Beta Kappa, 1981 - 1985

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 1990 - 2028
CT State Medical License 2026 - 2027
NJ State Medical License 2019 - 2027
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2016-2017
America's Top Doctors Castle Connolly, 2011-2014

Clinical Trials

Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer
COMPLETED
PHASE2
Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer
COMPLETED
PHASE2
Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer
COMPLETED
PHASE2

Publications & Presentations

PubMed

Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201.
Rachel N Grisham, Els Van Nieuwenhuysen, Alessandro D Santin, Véronique D'Hondt, Premal H Thaker
Gynecologic Oncology. 2026-09-16
A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell t...
Elizabeth E Hopp, Danielle Enserro, Susana Campos, Viola Chitiyo, Gloria Huang
Gynecologic Oncology. 2026-09-01
The pan-tumor landscape, allelic status, and genomic complexity of SMARCA4 alterations.
Matteo Repetto, Michael V Gormally, Jason Chang, Pier Selenica, Andrea Gazzo
Clinical Cancer Research. 2026-08-14

Journal Articles

A Phase 1 Dose-Escalation Study of Intraperitoneal Cisplatin, intravenous/intraperitoneal Paclitaxel, Bevacizumab, and Olaparib for Newly Diagnosed Ovarian Cancer
Roisin E O'Cearbhaill, Dmitriy Zamarin, Paul J Sabbatini, William P Tew, Carol Aghajanian, Jason A Konner, Gynecologic Oncology
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen Moore, Paul DiSilvestro, Carol Aghajanian, The New England Journal of Medicine

Lectures

Targeted Agents: Finding the Mark
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Scientific and Clinical Update in Gynecologic Oncology
Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania - 5/3/2013

Press Mentions

To Study Treatment Resistance in High-Grade Serous Ovarian Cancer, MSK Researchers Develop New ApproachOctober 1st, 2025
Ovarian Cancer Breakthrough: Whole-Genome Doubling KeyJuly 17th, 2025
Combination of Endometrial Cancer Drugs May Prolong Lives of WomenMarch 31st, 2023

Grant Support

Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterSLOAN-KETTERING INST CAN RESEARCH2019–2032
Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterSLOAN-KETTERING INST CAN RESEARCH2019–2032

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Association for Cancer Research - AACR
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment